Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
IVA - Inventiva
$18.70
-0.30(-1.58%)9:00:00 PM 1/21/2021
Stock Chart

Summary:

  • A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
  • RSI is at a high level of 81. A high level of RSI indicates the stock is overbought.
  • MACD is crossing MACD signal line at 0.4. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Stock news

    01/15/2021IVA
    Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

    Daix (France), January 15, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resou...

    01/6/2021IVA
    Inventiva annonce sa participation à la « 39th Annual J.P. Morgan Healthcare Conference »

    Daix (France), January 6, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Frédéric Cren, Chairman, CEO and cofounder of Inventiva, has been invited to present a corporate overview, followed by a Q&A session, and engage in 1x1 inve...

    01/5/2021IVA
    Inventiva announces design of Phase III clinical trial with lanifibranor in NASH

    * A single global Phase III clinical trial evaluating two doses of lanifibranor (800mg and 1200mg once daily) versus placebo is intended to support U.S. New Drug Application (NDA) / EU marketing authorization * Seeking of U.S. accelerated approval and EU conditional approval for lanifibranor to be based on 72-week histology analysis in approximately 900 patients * Use of primary composite endpoint combining NASH resolution and fibrosis improvement * Inventiva confirms planned initiation of ...

    12/8/2020IVA
    Is IVA A Good Stock To Buy Now?

    The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

    12/7/2020IVA
    Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis

    * The underlying studies aimed at characterizing the effects of the pan-PPAR agonist lanifibranor in two pre-clinical models of cirrhosis and in liver cells from cirrhotic patients * Lanifibranor showed clear beneficial effects leading to a marked improvement of fibrosis, portal hypertension and liver vascular resistance, three key elements of cirrhosis pathophysiology * Results in hepatic cells from cirrhotic patients further encourage the clinical evaluation of lanifibranor for the treatmen...

    11/24/2020IVA
    Inventiva to participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference

    Daix (France), November 24, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. During the conference, Inventiva will engage in 1x1 investor meetings as well...

    11/12/2020IVA
    Q3 2020 Financial Information

    * Cash and cash equivalents at €124.6m as of September 30, 2020, allowing the Company to finance its operating activities through Q4 2022   * Revenues of €0.3m for the first nine months of 2020 Daix (France), November 12, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significa...